| (Values in U.S. Thousands) | Oct, 2025 | Apr, 2025 | Jan, 2025 | Oct, 2024 | Apr, 2024 |
| Sales | 54 | 51 | 59 | 69 | 62 |
| Sales Growth | +6.99% | -14.29% | -14.32% | +11.79% | -4.25% |
| Net Income | -813 | -1,041 | -983 | -1,200 | -1,301 |
| Net Income Growth | +21.85% | -5.80% | +18.04% | +7.74% | -10.68% |
Medmira Inc (MIR.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.
Fiscal Year End Date: 07/31